Differences in the expression of telomerase and prostate-specific membrane antigen in non-advanced prostatic cancer

Folia Histochemica et Cytobiologica

Volumn 51, Issue 1, 2013, Pages 66-72

  Gasinska, Anna ^a   Luczynska, Elzbieta ^a   Wilk, Waclaw ^a   Cichocka, Anna ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

hTERT; Immunohistochemistry; Prostatic cancer; PSMA; Serum PSA; Telomerase

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE;

ADULT; ARTICLE; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; CYTOPLASM; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION;

EID: 84877031431     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.5603/FHC.2013.0010     Document Type: Article

References (40)

1. Bickers B, Aukim-Hastie C. New molecular biomarkers for the prognosis and management of prostate cancer-the post PSA era. Anticancer Res. 2009;29:3289-3298.
2. Welch HG, Fisher ES, Gottlieb DJ, Barry MJ. Detection of prostate cancer via biopsy in the medicare-SEER population during the PSA era. J Natl Cancer Inst. 2007;99:1395-1400.
3. Yuen JS, Thng CH. Endorectal magnetic resonance imaging and spectroscopy for detection of foci in men with prior negative transrectal ultrasound prostate biopsy. J Urol. 2004;171: 1482-1486.
4. Bjartell A, Montironi R, Berney MD, Egevad L. Tumor markers in prostate cancer II: Diagnostic and prognostic cellular biomarkers. Acta Oncol. 2011;50: 76-84.
5. Counter Ch M, Meyerson M, Eaton EN, Ellisen LW, Dickinson Caddl, Haber DA et al. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene 1998;16:1217-1222.
6. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PLC et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-2015.
7. Hiyama E, Hiyama K. Telomerase as tumor marker. Cancer Lett. 2003;194:221-233.
8. Lin Y, Uemura H, Fujinami K, Hosaka M, Harada M, Kubota Y et al. Telomerase activity in primary prostate cancer. J Urol. 1997;157:1161-1165.
9. Zhang W, Kapusta LR, Slingerland JM, Klotz LH. Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium. Cancer Res. 1998;58:619-621.
10. Sommerfeld HJ, Meeker AK, Piatyszek MA, Bova GS, Shay JW, Coffey DS. Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res. 1996;56:218--222.
11. Iczkowski KA, Pantazis CG, McGregor DH, Wu Y, Tawfik OW. Telomerase reverse transcriptase subunit immunoreactiviy. A marker for high-grade carcinoma. Cancer 2002;96: 2487-2493.
12. Wang Z, Ramin SA, Tsai C, Lui P, Ruckle HC, Beltz RE et al. Telomerase activity in prostate sextant needle cores from radical prostatectomy specimens. Urol Oncol. 2001;6:57-62.
13. Chung HK, Cheong Ch, Song J, Lee HW. Extratelomeric functions of telomerase. Curr Mol Med. 2005;5:233-241.
14. Sung YH, Choi YS, Cheong C, Lee HW. The pleiotropy of telomerase against cell death. Mol Cells 2005;19:303-309.
15. Jagadeesh S, Banerjee PP. Telomerase reverse transcriptase regulates the expression of a key cell cycle regulator, cyclin D1. Biochem Biophys Res Commun. 2006;347:774-780.
16. Israeli RS, Powell CT, Fair WR, Heston WDW. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antige. Cancer Res. 1993;53:227-230.
17. Chang SS. Overview of prostate-specific membrane antigen. Rev Urol. 2004;6 (suppl 10) S13-S18.
18. Pinto JT, Suffoletto BP, Berzin TM, Qiao H, Lin S, Tong WP et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res. 1996;2:1445-1451.
19. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma. A study of 184 cases. Cancer 1998;82:2256-2261.
20. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostatespecific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998;52:637-640.
21. Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res.1998;58:4055-4060.
22. Liu T, Wu LY, Berkman CE. Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption. Cancer Lett. 2010;296:106-112.
23. Osborne JR, Akhtar NH, Vallabhajosula S, Anand A, Deh K et al. Prostate-speciifc membrane antigen-based imaging. Urol Oncol. 2012;31:144-154.
24. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual, 7th ed.; New York: Springer; 2010:457-464.
25. Gleason DF. The Veterans Administration Cooperative Urological Research Group: histological grading and clinical staging of prostatic carcinoma. In: Tannenbaum M, ed. Urologic Pathology: The prostate. Philadelphia: Lea and Febiger; 1997:171-197.
26. Puebla-Mora AG, Heras A, Cano-Valdez AM, Dominiquez- -Malagon H. Human telomerase and?-methyl-coenzyme A racemase in prostatic carcinoma. A comparative immunohistochemical study. An Diagn Pathol. 2006;10:205-208.
27. Latil A, Vidaud D, Valeri A, Fournier G, Vidaud M et al. hTERT expression correlates with MYC over-expression in human prostate cancer. Int J Cancer. 2000:89:172-176.
28. Ahmed S, Passos JF, Birker MJ, Beckmann T, Brings S. Telomerase does not counteract shortening but protects mitochondrial function under oxidative stress. J Cell Sci. 2008;121: 1046-1053.
29. Bollmann FM. The many faces of telomerase: emerging extratelomeric effects. BioEssays. 2008;30:728-732.
30. Saretzki G. Telomerase, mitochondria and oxidative stress. Exp Geront. 2009;44:485-492.
31. Luczynska E, Gasinska A, Wilk W. Expression of Ki-67 (MIB-1) and GLUT-1 proteins in non-advanced prostatic cancer. Pol J Pathol. 2012;63 272-277.
32. Maser RS, DePinho RA. Keeping telomerase in its place. Nature Med. 2002;8:934-936.
33. Wang Y, Kreisberg JI, Ghosh PM. Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. Curr Cancer Drug Targets. 2007;7: 591-604.
34. Moehren U, Papaioannou M, Reeb Ch, Grasselli A, Nanni S, Asim M et al. Wild-type but not mutant androgen receptor inhibits expression of the hTERT telomerase subunit: a novel role of AR mutation for prostate cancer development. FASEB J. 2008;22:1258-1267.
35. Iczkowski K, Huang W, Mazzucchelli R, Pantazis CG, Stevens GR, Montironi R. Androgen ablation therapy for prostate carcionoma suppresses the immunoreactive telomerase subunit hTERT. Cancer. 2004;100:294-299.
36. Wright GL, Grob MB, Heley C, Grossman, Newhall K, Petrylak D et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996;48:326-334.
37. Jemaa A, Bouraoui Y, Sallami S, Banasr A, Ben Rais N, Quertani L et al. Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies. J Exp Clin Cancer Res. 2010; 29: 171-180.
38. Perner S, Hofer MD, Kim R, Moller P, Hautmann RE et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007;38:696-701.
39. Rajasekaran SA, Christiansen JJ, Schmid I, Oshima E, Sakamoto K, Weinstein J et al. Prostate-specific membrane antigen associates with anaphase-promoting complex and induces chromosomal instability. Mol Cancer Ther. 2008;7:2142-2151.
40. Akhtar NH, Pail O, Saran A, Tyrell L, Tagawa ST. Prostatespecific membrane antigen-based therapeutics. Adv Urol. 2012; doi:10.1155/2012/973820.